UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin

The Journal of biological chemistry, 2011-03, Vol.286 (9), p.7290-7300

2011

Volltextzugriff (PDF)

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (3), p.923-928

2008

Volltextzugriff (PDF)

Novel EP4 Receptor Agonist‐Bisphosphonate Conjugate Drug (C1) Promotes Bone Formation and Improves Vertebral Mechanical Properties in the Ovariectomized Rat Model of Postmenopausal Bone Loss

Journal of bone and mineral research, 2015-04, Vol.30 (4), p.670-680

2015

Volltextzugriff (PDF)

Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

Bioorganic & medicinal chemistry, 2012-03, Vol.20 (6), p.2131-2140

2012

Volltextzugriff (PDF)

Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis

Journal of medicinal chemistry, 2017-08, Vol.60 (16), p.7012-7028

2017

Volltextzugriff (PDF)

Design and synthesis of an all-in-one 3-(1,1-difluoroprop-2-ynyl)-3H-diazirin-3-yl functional group for photo-affinity labeling

Bioorganic & medicinal chemistry, 2009-08, Vol.17 (15), p.5388-5395

2009

Volltextzugriff (PDF)

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein

STAR protocols, 2022-06, Vol.3 (2), p.101258-101258, Article 101258

2022

Volltextzugriff (PDF)

Identification of Pyruvate Kinase in Methicillin-Resistant Staphylococcus aureus as a Novel Antimicrobial Drug Target

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2042-2053

2011

Volltextzugriff (PDF)

Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta

Bone (New York, N.Y.), 2021-04, Vol.145, p.115867-115867, Article 115867

2021

Volltextzugriff (PDF)

The promise and peril of chemical probes

Nature chemical biology, 2015-08, Vol.11 (8), p.536-541

2015

Volltextzugriff (PDF)

Targeting therapeutics to bone by conjugation with bisphosphonates

Current opinion in pharmacology, 2018-06, Vol.40, p.87-94

2018

Volltextzugriff (PDF)

In Vivo Bone Effects of a Novel Bisphosphonate‐EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model

JBMR plus, 2019-12, Vol.3 (12), p.e10237-n/a

2019

Volltextzugriff (PDF)

E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Nature cell biology, 2021-07, Vol.23 (7), p.796-807

2021

Volltextzugriff (PDF)

Determination of the Rat in Vivo Pharmacokinetic Profile of a Bone-Targeting Dual-Action Pro-Drug for Treatment of Osteoporosis

Bioconjugate chemistry, 2015-06, Vol.26 (6), p.1095-1103

2015

Volltextzugriff (PDF)

Large-Scale Virtual Screening for the Discovery of SARS-CoV‑2 Papain-like Protease (PLpro) Non-covalent Inhibitors

Journal of chemical information and modeling, 2023-04, Vol.63 (7), p.2158-2169

2023

Volltextzugriff (PDF)

A Novel Anabolic Conjugate (C3) in the Matrix of Dicalcium Phosphate Onlay Block Grafts for Achieving Vertical Bone Augmentation: An Experimental Study on Rabbit Calvaria

The International journal of oral and maxillofacial implants, 2019-07, Vol.34 (4), p.e51–e63-e63

2019

Volltextzugriff (PDF)

Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del

Molecular pharmacology, 2018-08, Vol.94 (2), p.917-925

2018

Volltextzugriff (PDF)

Further investigation of inhibitors of MRSA pyruvate kinase: Towards the conception of novel antimicrobial agents

European journal of medicinal chemistry, 2017-01, Vol.125, p.1-13

2017

Volltextzugriff (PDF)

Improved bone regeneration using bone anabolic drug conjugates (C3 and C6) with deproteinized bovine bone mineral as a carrier in rat mandibular defects

Journal of periodontology (1970), 2020-11, Vol.91 (11), p.1521-1531

2020

Volltextzugriff (PDF)

Achieving enhanced bone regeneration using monetite granules with bone anabolic drug conjugates (C3 and C6) in rat mandibular defects

Journal of biomedical materials research. Part B, Applied biomaterials, 2020-08, Vol.108 (6), p.2670-2680

2020

Volltextzugriff (PDF)

Development of 2‑(5,6,7-Trifluoro‑1H‑Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function‑3 for the Treatment of Castration-Resistant Prostate Cancer

Journal of medicinal chemistry, 2021-10, Vol.64 (20), p.14968-14982

2021

Volltextzugriff (PDF)

Development of fluorescent peptide substrates and assays for the key autophagy-initiating cysteine protease enzyme, ATG4B

Bioorganic & medicinal chemistry, 2015-07, Vol.23 (13), p.3237-3247

2015

Volltextzugriff (PDF)

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

Molecular cancer therapeutics, 2016-12, Vol.15 (12), p.2936-2945

2016

Volltextzugriff (PDF)

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

Bioorganic & medicinal chemistry letters, 2003-03, Vol.13 (6), p.1129-1132

2003

Volltextzugriff (PDF)

Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions

ACS pharmacology & translational science, 2021-04, Vol.4 (2), p.908-925

2021

Volltextzugriff (PDF)

1 – 25 von 2.357

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.107)
Mit Volltextzugriff
(1.985)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Novel EP4 Receptor Agonist‐Bisphosphonate Conjugate Drug (C1) Promotes Bone Formation and Improves Vertebral Mechanical Properties in the Ovariectomized Rat Model of Postmenopausal Bone Loss

Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis

Design and synthesis of an all-in-one 3-(1,1-difluoroprop-2-ynyl)-3H-diazirin-3-yl functional group for photo-affinity labeling

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein

Identification of Pyruvate Kinase in Methicillin-Resistant Staphylococcus aureus as a Novel Antimicrobial Drug Target

Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta

The promise and peril of chemical probes

Targeting therapeutics to bone by conjugation with bisphosphonates

In Vivo Bone Effects of a Novel Bisphosphonate‐EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model

E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Determination of the Rat in Vivo Pharmacokinetic Profile of a Bone-Targeting Dual-Action Pro-Drug for Treatment of Osteoporosis

Large-Scale Virtual Screening for the Discovery of SARS-CoV‑2 Papain-like Protease (PLpro) Non-covalent Inhibitors

A Novel Anabolic Conjugate (C3) in the Matrix of Dicalcium Phosphate Onlay Block Grafts for Achieving Vertical Bone Augmentation: An Experimental Study on Rabbit Calvaria

Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del

Further investigation of inhibitors of MRSA pyruvate kinase: Towards the conception of novel antimicrobial agents

Improved bone regeneration using bone anabolic drug conjugates (C3 and C6) with deproteinized bovine bone mineral as a carrier in rat mandibular defects

Achieving enhanced bone regeneration using monetite granules with bone anabolic drug conjugates (C3 and C6) in rat mandibular defects

Development of 2‑(5,6,7-Trifluoro‑1H‑Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function‑3 for the Treatment of Castration-Resistant Prostate Cancer

Development of fluorescent peptide substrates and assays for the key autophagy-initiating cysteine protease enzyme, ATG4B

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions

Suchergebnisse filtern